Galmed Pharmaceuticals (GLMD) Common Equity (2013 - 2026)
Galmed Pharmaceuticals (GLMD) posted quarterly Common Equity of $13.9 million for Q1 2026, down 17.35% year-over-year from $16.9 million in Q1 2025, and down 11.62% quarter-over-quarter from $15.8 million in Q4 2025.
Galmed Pharmaceuticals (GLMD) Common Equity (2013 - 2026) Analysis & Trends
Galmed Pharmaceuticals' Common Equity history runs 14 years deep, the most recent figure standing at $13.9 million for Q1 2026.
- In Q1 2026, Common Equity fell 17.35% year-over-year to $13.9 million; the TTM figure through Mar 2026 stood at $13.9 million (down 17.35% YoY), while the FY2025 annual figure was $15.8 million, up 199.29% from the prior year.
- Common Equity for Q1 2026 stood at $13.9 million, down from $15.8 million in the prior quarter.
- The five-year high for Common Equity was $24.4 million in Q1 2022, with the low at -$15.9 million in Q4 2024.
- The 5-year median for Common Equity is $15.5 million (2023), against an average of $14.1 million.
- The sharpest annual moves came in 2024 and 2025: Common Equity slumped 214.53% in 2024, then surged 199.29% in 2025.
- Galmed Pharmaceuticals' Common Equity stood at $13.4 million in 2022, then rose by 3.4% to $13.9 million in 2023, then plunged by 214.53% to -$15.9 million in 2024, then soared by 199.29% to $15.8 million in 2025, then declined by 11.62% to $13.9 million in 2026.
- Business Quant data shows GLMD's Common Equity at $13.9 million in Q1 2026, $15.8 million in Q4 2025, and $19.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Galmed Pharmaceuticals | 2.39 Mn | -9.49 Mn | - | 13.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.95 Mn |
| Dec 31, 2025 | 15.78 Mn |
| Sep 30, 2025 | 19.11 Mn |
| Jun 30, 2025 | 20.52 Mn |
| Mar 31, 2025 | 16.88 Mn |
| Dec 31, 2024 | -15.90 Mn |
| Sep 30, 2024 | 18.44 Mn |
| Jun 30, 2024 | 11.79 Mn |
| Mar 31, 2024 | 12.76 Mn |
| Dec 31, 2023 | 13.88 Mn |
| Sep 30, 2023 | 15.46 Mn |
| Jun 30, 2023 | 10.55 Mn |
| Mar 31, 2023 | 11.99 Mn |
| Dec 31, 2022 | 13.42 Mn |
| Sep 30, 2022 | 15.75 Mn |
| Jun 30, 2022 | 20.71 Mn |
| Mar 31, 2022 | 24.37 Mn |
| Dec 31, 2021 | 30.50 Mn |
| Sep 30, 2021 | 37.68 Mn |
| Jun 30, 2021 | 45.00 Mn |